Cargando…

Disparity in outcomes of melanoma adjuvant immunotherapy by demographic profile

BACKGROUND: Randomized comparisons have demonstrated survival benefit of adjuvant immunotherapy in node-positive melanoma patients but have limited power to determine if this benefit persists across various demographic factors. MATERIALS & METHODS: We assessed the impact of demographic factors o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ikeguchi, Alexandra, Machiorlatti, Michael, Vesely, Sara K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426750/ https://www.ncbi.nlm.nih.gov/pubmed/32821375 http://dx.doi.org/10.2217/mmt-2020-0002

Ejemplares similares

Development of thrombocytopenia is associated with improved survival in patients treated with immunotherapy
por: Assi, Hussein A, et al.
Publicado: (2020)

Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy
por: Bhave, Prachi, et al.
Publicado: (2023)

Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews
por: Livingstone, Ann, et al.
Publicado: (2021)

Adjuvant effect of IRES-based single-stranded RNA on melanoma immunotherapy
por: Kwak, Hye Won, et al.
Publicado: (2022)

Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond
por: Chen, Lanyi Nora, et al.
Publicado: (2023)

Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy
por: Atkinson, Thomas M, et al.
Publicado: (2023)

Clinical and Demographic Profile of Cutaneous Melanoma: Pakistani Perspective
por: Saaiq, Muhammad, et al.
Publicado: (2020)

Obesity in Total Hip Arthroplasty: Demographic Disparities and Outcome Incongruities
por: Wilkie, Wayne A, et al.
Publicado: (2020)

Effective Melanoma Immunotherapy in Mice by the Skin-Depigmenting Agent Monobenzone and the Adjuvants Imiquimod and CpG
por: van den Boorn, Jasper G., et al.
Publicado: (2010)

Adjuvant Therapy: Melanoma
por: Davar, Diwakar, et al.
Publicado: (2011)

Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma—A Discrete Choice Experiment
por: Livingstone, Ann, et al.
Publicado: (2023)

Management of metastatic melanoma in Texas: disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors
por: Olateju, Olajumoke A., et al.
Publicado: (2023)

Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis
por: Lattanzi, Michael, et al.
Publicado: (2018)

Adjuvant Probiotics and the Intestinal Microbiome: Enhancing Vaccines and Immunotherapy Outcomes
por: Vitetta, Luis, et al.
Publicado: (2017)

An Unusual Case of Malignant Melanoma with Metastasis to the Placenta During Pregnancy
por: Garcia-Ramiu, Kenny, et al.
Publicado: (2022)

Dieulafoy's Lesion: Decade-Long Trends in Hospitalizations, Demographic Disparity, and Outcomes
por: Chakinala, Raja Chandra, et al.
Publicado: (2020)

Adjuvant Treatment of Melanoma
por: Moreno Nogueira, J. A., et al.
Publicado: (2013)

Immunotherapy of melanoma
por: Haanen, John B.A.G.
Publicado: (2013)

Demographic and Urbanization Disparities of Liver Transplantation in Taiwan
por: Wen, Pei-Hung, et al.
Publicado: (2018)

Advances in immunotherapy for melanoma
por: Redman, Jason M., et al.
Publicado: (2016)

Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect
por: Nava, Sara, et al.
Publicado: (2021)

A pretreatment transcriptomic signature that predicts outcomes of immunotherapy in melanoma
por: Hu, Junjie, et al.
Publicado: (2022)

Melanoma immunotherapy
por: Garg, Abhishek D., et al.
Publicado: (2015)

Immunotherapy of melanoma
por: Lugowska, Iwona, et al.
Publicado: (2018)

Adjuvanted Immunotherapy Approaches for Peanut Allergy
por: Johnson-Weaver, Brandi T., et al.
Publicado: (2018)

Sex and Gender Disparities in Melanoma
por: Bellenghi, Maria, et al.
Publicado: (2020)

Emerging Adjuvants for Cancer Immunotherapy
por: Hu, Hong-Guo, et al.
Publicado: (2020)

Curcumin as an Adjuvant to Cancer Immunotherapy
por: Paul, Silpita, et al.
Publicado: (2021)

Disparities in diabetes care: role of the patient's socio-demographic characteristics
por: Wilf-Miron, Rachel, et al.
Publicado: (2010)

Demographic disparities in receipt of care at a comprehensive cancer center
por: Kirtane, Kedar, et al.
Publicado: (2023)

Benefits of specialist severe asthma management: demographic and geographic disparities
por: Redmond, Charlene, et al.
Publicado: (2022)

Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy
por: Verdura, Sara, et al.
Publicado: (2019)

A real‐world study of adjuvant anti‐PD ‐1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations
por: Sun, Wei, et al.
Publicado: (2023)

Adjuvant and neoadjuvant therapies in melanoma
por: Lim, Kok Haw Jonathan, et al.
Publicado: (2020)

Adjuvant interferon in the treatment of melanoma
por: Middleton, M R
Publicado: (1999)

Adjuvant interferon in the treatment of melanoma
por: Kirkwood, J M
Publicado: (2000)

Epidemiologic Trends of Cutaneous T-Cell Lymphoma in Arkansas Reveals Demographic Disparities
por: Kayishunge, Delice, et al.
Publicado: (2022)

Utility of adjuvant systemic therapy in melanoma
por: Eggermont, A. M. M., et al.
Publicado: (2009)

Adjuvant therapy for high-risk melanoma
por: Eggermont, Alexander M.M.
Publicado: (2013)

Disparities in digital reporting of illness: A demographic and socioeconomic assessment
por: Henly, Samuel, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_m0t1h6pj9gldhmieu1eok9655e